Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN85216856
ISRCTN85216856
Active, not recruiting
Phase 2

Investigating the use of convalescent plasma from patients who have recovered from COVID-19 in the management of Ecuadorian patients infected with SARS-CoV-2 with clinical deterioration: IMPACT

niversidad Tecnológica Equinoccial0 sites200 target enrollmentMay 11, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
niversidad Tecnológica Equinoccial
Enrollment
200
Status
Active, not recruiting
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 11, 2020
End Date
December 31, 2020
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversidad Tecnológica Equinoccial

Eligibility Criteria

Inclusion Criteria

  • •1\. Aged \=18 years
  • •2\. Clinical, molecular (using IgM/IgG or RT\-PCR), or lung imaging diagnosis of COVID\-19
  • •3\. Deterioration of previously normal lung function defined as SaO2 of \<90% in 0\.5 FiO2, and/or a higher requirement of O2 than in the previous 24h
  • •4\. A score of 5 to 7 on the early warning scale for COVID\-19 patients or a SOFA score between 2 and 10
  • •5\. Informed consent provided by patients or their representatives

Exclusion Criteria

  • •1\. Diagnosis and/or treatment for cancer
  • •2\. HIV infection
  • •3\. Currently receiving immunosuppressants for a condition other than SARS\-CoV2 infection
  • •4\. Superimposed systemic infections
  • •5\. Liver or kidney failure
  • •6\. COPD, previous pulmonary fibrosis, and/or restrictive lung disease
  • •7\. Have received previous transfusions

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 2
se of plasma of cured person to treat patient with severe covid-19Coronavirus infection, transfusion, C23, A00-B99, Coronavirus OC43, Human.A00-B99
RBR-7f4mt9fHemocentro de Ribeirão Preto
Recruiting
Not Applicable
se of Convalescent Plasma in the treatment of COVID-19
IRCT20200414047072N1Hilton Pharma Pvt. Ltd.357
Recruiting
Not Applicable
A randomized, double blinded clinical trial of convalescent plasma compared to standard plasma for treatment of hospitalized non-ICU patients with COVID-19 infectionsCOVID-19
NL-OMON23835eiden University Medical Center430
Not yet recruiting
Not Applicable
Benchmarking therapeutic plasma exchange for the indications in a tertiary care centre as per the international guidelines.
CTRI/2023/12/060962Kasturba Medical College PG thesis grant
Recruiting
Phase 2
Evaluation of the effect of plasmapheresis in the treatment of Covid 19
IRCT20200405046958N2Mashhad University of Medical Sciences42